Clinical Drug Investigation

, Volume 35, Supplement 1, pp 19–27 | Cite as

The Diagnosis and Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia by Primary Care Family Physicians in Portugal

Original Research Article



The shift towards primarily pharmacological management of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) has led to an increasing proportion of patients being treated in the primary care setting.


Two related studies were undertaken in Portugal. The first was a survey of primary care family physicians regarding the management of LUTS/BPH. The second was a cross-sectional study of the records of patients with suspected or confirmed LUTS/BPH managed by the surveyed physicians.


One hundred and sixty-three physicians were surveyed between 16 June 2012 and 10 February 2013 and 2,988 patients were identified (mean age 68 years). While 80 % of physicians would order diagnostic tests for patients reporting symptoms, only 2.5 % would initiate treatment based on reported symptoms alone. Only 1 % would refer patients directly to a urologist for diagnosis, and 75 % would only refer patients after an inadequate response to treatment in the primary care setting. Management practices varied according to physicians’ age and experience. Nocturia was both the most common and the most bothersome symptom. Erectile dysfunction was reported by 51 % of patients and 81 % had hypertension, hypercholesterolaemia and/or diabetes mellitus. Diagnosis and treatment of LUTS/BPH differed for older patients, those with comorbidities and those with more severe nocturia at presentation.


Primary care physicians in Portugal usually diagnose and treat patients with LUTS/BPH rather than refer them to a urologist. Physicians’ age and experience, and patients’ age, comorbidities and symptom severity affect the management of LUTS/BPH in primary care in Portugal.


Erectile Dysfunction Benign Prostatic Hyperplasia Lower Urinary Tract Symptom International Prostate Symptom Score Urinary Symptom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We thank Simone Boniface of Springer Healthcare Communications and Raewyn Poole, on behalf of Springer Healthcare Communications, for medical writing assistance. We also thank Ray Hill for assistance with post-submission revisions, on behalf of Springer Healthcare Communications. All medical writing assistance was funded by Tecnimede, S.A.

Conflict of interest statement

Júlio Fonseca is a physician at the Department of Urology, Hospital Beatriz Angelo, Loures and British Hospital, Lisbon, Portugal. He is an occasional unpaid lecturer in Tecnimede-sponsored events. Carlos Martins da Silva is an employee of the Department of Urology, Hospital de S. João, Faculdade de Medicina do Porto, Porto, Portugal. He has received consultant honoraria from Tecnimede.

This paper, to be published in Clinical Drug Investigation, is based on two field surveys conducted by Springer SBM, which were sponsored by Tecinimede.

Supplementary material

40261_2014_256_MOESM1_ESM.docx (50 kb)
Supplementary material 1 (DOCX 50 kb)


  1. 1.
    Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):443–59, v–vi.Google Scholar
  2. 2.
    Lee C, Kozlowski JM, Grayhack JT. Intrinsic and extrinsic factors controlling benign prostatic growth. Prostate. 1997;31(2):131–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Wei JT, Calhoun EA, Jacobsen SJ. Urologic diseases in America: Interim Compendium. Chapter 2: benign prostatic hyperplasia. 2004. Accessed 2013.
  4. 4.
    Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–61.CrossRefPubMedGoogle Scholar
  5. 5.
    Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep. 2010;5(4):212–8.CrossRefPubMedCentralPubMedGoogle Scholar
  6. 6.
    Thorpe A, Neal D. Benign prostatic hyperplasia. Lancet. 2003;361(9366):1359–67.CrossRefPubMedGoogle Scholar
  7. 7.
    Wei JT, Miner MM, Steers WD, et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol. 2011;186(3):971–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Roehrborn CG. Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Med Clin North Am. 2011;95(1):87–100.CrossRefPubMedGoogle Scholar
  9. 9.
    Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64(1):118–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Sandhu JS. Therapeutic options in the treatment of benign prostatic hyperplasia. Patient Prefer Adher. 2009;3:213–23.CrossRefGoogle Scholar
  11. 11.
    Roehrborn CG, Nuckolls JG, Wei JT, et al. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int. 2007;100(4):813–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Hutchison A, Farmer R, Chapple C, et al. Characteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol. 2006;50(3):555–61 (discussion 62).CrossRefPubMedGoogle Scholar
  13. 13.
    Coyne KS, Zhou Z, Bhattacharyya SK, et al. The prevalence of nocturia and its effect on health-related quality of life and sleep in a community sample in the USA. BJU Int. 2003;92(9):948–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Oelke M, Wiese B, Berges R. Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older. World J Urol. 2014;32(5):1155–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637–49.CrossRefPubMedGoogle Scholar
  16. 16.
    McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185(5):1793–803.CrossRefPubMedGoogle Scholar
  17. 17.
    Trueman P, Hood SC, Nayak US, et al. Prevalence of lower urinary tract symptoms and self-reported diagnosed ‘benign prostatic hyperplasia’, and their effect on quality of life in a community-based survey of men in the UK. BJU Int. 1999;83(4):410–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of UrologyHospital Beatriz AngeloLouresPortugal
  2. 2.British HospitalLisbonPortugal
  3. 3.Department of Urology, Faculdade de Medicina do PortoHospital de S. JoãoPortoPortugal

Personalised recommendations